{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:14:17Z","timestamp":1784762057908,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"DOI":"10.1007\/s12311-024-01705-x","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T09:02:06Z","timestamp":1716282126000},"page":"2193-2196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Potential Clinical Benefit of Very Long Chain Fatty Acid Supplementation in Spinocerebellar Ataxia Type 34"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3061-6538","authenticated-orcid":false,"given":"Jos\u00e9","family":"Gazulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Berciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"1705_CR1","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1212\/NXG.0000000000000403","volume":"6","author":"M Beaudin","year":"2020","unstructured":"Beaudin M, Sellami L, Martel C, Touzel-Desch\u00eanes L, Houle G, Martineau L, et al. Characterization of the phenotype with cognitive impairment and protein mislocalization in SCA34. Neurol Genet. 2020;6:e403.","journal-title":"Neurol Genet"},{"key":"1705_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamaneurol.2015.0610","volume":"72","author":"K Ozaki","year":"2015","unstructured":"Ozaki K, Doi H, Mitsui J, Sato N, Iikuni Y, Majima T, et al. A novel mutation in ELOVL4 leading to spinocerebellar ataxia (SCA) with the hot cross bun sign but lacking erythrokeratodermia: a broadened spectrum of SCA34. JAMA Neurol. 2015;72:797\u2013805.","journal-title":"JAMA Neurol"},{"key":"1705_CR3","doi-asserted-by":"publisher","first-page":"100317","DOI":"10.1016\/j.jlr.2022.100317","volume":"64","author":"YK Gyening","year":"2023","unstructured":"Gyening YK, Chauhan NK, Tytanic M, Ea V, Brush RS, Agbaga MP. ELOVL4 mutations that cause spinocerebellar ataxia-34 differentially alter very long chain fatty acid biosynthesis. J Lipid Res. 2023;64:100317.","journal-title":"J Lipid Res"},{"key":"1705_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s40478-023-01628-4","volume":"11","author":"YK Gyening","year":"2023","unstructured":"Gyening YK, Boris K, Cyril M, Brush RS, Nassogne MC, Agbaga MP. A novel ELOVL4 variant, L168S, causes early childhood-onset spinocerebellar ataxia-34 and retinal dysfunction: a case report. Acta Neuropathol Commun. 2023;11:131.","journal-title":"Acta Neuropathol Commun"},{"key":"1705_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2013.6337","volume":"71","author":"M Cadieux-Dion","year":"2014","unstructured":"Cadieux-Dion M, Turcotte-Gauthier M, Noreau A, Martin C, Meloche C, Gravel M, et al. Expanding the clinical phenotype associated with ELOVL4 mutation: study of a large french-canadian family with autosomal dominant spinocerebellar ataxia and erythrokeratodermia. JAMA Neurol. 2014;71:470\u20135.","journal-title":"JAMA Neurol"},{"key":"1705_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamaneurol.2015.0888","volume":"72","author":"CV Bourassa","year":"2015","unstructured":"Bourassa CV, Raskin S, Serafini S, Teive HA, Dion PA, Rouleau GA. A new ELOVL4 mutation in a case of spinocerebellar ataxia with erythrokeratodermia. JAMA Neurol. 2015;72:942\u20133.","journal-title":"JAMA Neurol"},{"key":"1705_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10985549.2023.2169563","volume":"43","author":"Y Tamura","year":"2023","unstructured":"Tamura Y, Sassa T, Nishizawa T, Kihara A. Incomplete elongation of ultra-long-chain polyunsaturated Acyl-CoAs by the fatty acid elongase ELOVL4 in spinocerebellar ataxia type 34. Mol Cell Biol. 2023;43:1\u201317.","journal-title":"Mol Cell Biol"},{"key":"1705_CR8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12311-023-01522-8","volume":"23","author":"M Nishide","year":"2024","unstructured":"Nishide M, Le Marquand K, Davis MR, Halm\u00e1gyi GM, Fellner A, Narayanan RK, et al. Two new families and a literature review of ELOVL4-associated spinocerebellar ataxia type 34. Cerebellum. 2024;23:268\u201377.","journal-title":"Cerebellum"},{"key":"1705_CR9","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1212\/NXG.0000000000000357","volume":"5","author":"C Xiao","year":"2019","unstructured":"Xiao C, Binkley EM, Rexach J, Knight-Johnson A, Khemani P, Fogel BL, et al. A family with spinocerebellar ataxia and retinitis pigmentosa attributed to an ELOVL4 mutation. Neurol Genet. 2019;5:e357.","journal-title":"Neurol Genet"},{"key":"1705_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s40478-021-01272-w","volume":"9","author":"K Ozaki","year":"2021","unstructured":"Ozaki K, Irioka T, Uchihara T, Yamada A, Nakamura A, Majima T, et al. Neuropathology of SCA34 showing widespread oligodendroglial pathology with vacuolar white matter degeneration: a case study. Acta Neuropathol Commun. 2021;9:172.","journal-title":"Acta Neuropathol Commun"},{"key":"1705_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ana.25059","volume":"82","author":"M Manes","year":"2017","unstructured":"Manes M, Alberici A, Di Gregorio E, Boccone L, Premi E, Mitro N, et al. Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38. Ann Neurol. 2017;82:615\u201321.","journal-title":"Ann Neurol"},{"key":"1705_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.parkreldis.2019.02.040","volume":"63","author":"M Manes","year":"2019","unstructured":"Manes M, Alberici A, Di Gregorio E, Boccone L, Premi E, Mitro N, et al. Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: an open label extension study. Parkinsonism Relat Disord. 2019;63:191\u20134.","journal-title":"Parkinsonism Relat Disord"},{"key":"1705_CR13","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s00415-020-09840-1","volume":"267","author":"J Gazulla","year":"2020","unstructured":"Gazulla J, Orduna-Hospital E, Benavente I, Rodr\u00edguez-Valle A, Osorio-Caicedo P, Alvarez-de Andr\u00e9s S, et al. Contributions to the study of spinocerebellar ataxia type 38 (SCA38). J Neurol. 2020;267:2288\u201395.","journal-title":"J Neurol"},{"key":"1705_CR14","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1007\/s00415-022-11138-3","volume":"269","author":"J Gazulla","year":"2022","unstructured":"Gazulla J, Benavente I, Garc\u00eda-Gonz\u00e1lez E, Berciano J. Two-year follow-up of docosahexaenoic acid supplementation in spinocerebellar ataxia type 38 (SCA38). J Neurol. 2022;269:5643\u20136.","journal-title":"J Neurol"}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-024-01705-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-024-01705-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-024-01705-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T02:13:14Z","timestamp":1729303994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12311-024-01705-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1007\/s12311-024-01705-x","relation":{},"ISSN":["1473-4230"],"issn-type":[{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"13 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"in accordance with the local institutional ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The listed authors qualify for authorship according to the following criteria.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}